Dishman Pharmaceuticals spurted 8.63% to Rs 218.50 after its recently acquired company Carbogen-Amcis AG
Dishman Pharmaceuticals spurts. Dishman Pharmaceuticals spurted 8.63% to Rs 218.50 after its recently acquired company Carbogen-Amcis AG, announced a capital investment of $ 8 million for their additional Oncology production line
The counter clocked volumes of 3.19 lakh shares on BSE. The stock had surged 6.54% on Thursday, to Rs 201.15, ahead of the announcement.
Carbogen-Amcis AG, a Swiss firm which Dishman acquired recently would invest $8 million to set up another oncology production line. The investment would be funded from Carbogen-Amcis' cash accruals.
In October, Dishman Pharmaceuticals announced that Dishman Infrastructure has obtained 'in principle' approval from the Ministry of Commerce and Industry, Government of India for setting up one engineering SEZ and one pharmaceuticals and Fine Chemicals SEZ in Gujarat. The total investment will be around Rs 650 crore for both the SEZs, to be made over next three to five years and will be funded through a combination of debt/equity and internal accruals.
Dishman Pharmaceuticals is a Gujarat-based pharmaceutical company focussing on contract manufacturing for MNCs.
The company registered a marginal 0.20% rise in net profit for Q2 September 2006 to Rs 12.31 crore compared to Rs 12.29 crore in Q2 September 2005. Net sales rose 14.90% to Rs 60.59 crore (Rs 52.74 crore).
